PRME on Nasdaq
Prime Medicine, Inc.
American biological products company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Ocugen, Zeo ScientifiX, Inc. or CG Oncology, Inc., or pick any stock.
- TickerPRME on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersCambridge, Massachusetts1
- Incorporated inDE2
- Business address60 First St., Cambridge, Ma 021412
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
See how the biggest companies compare on our leaderboards
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks. We believe Prime Editing represents the most versatile and precise method for rewriting, replacing, or repairing DNA sequences and may allow us to address a broad spectrum of diseases with an improved safety and specificity profile relative to earlier editing technologies. We are advancing a pipeline of wholly owned in vivo programs targeting diseases of the liver, Cystic Fibrosis, or CF, programs with the support of the Cystic…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-4498.1%Operating margin4
-4342.4%Net margin4
55.3%Revenue growth, 20254
-166.4%Return on equity4
-$167.1MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$160.6M
Out of $4.6M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue | $4.6M | $3.0M |
| Research and development | $160.6M | $155.3M |
| General and administrative | $52.3M | $50.2M |
| Total operating expenses | $213.0M | $205.4M |
| Loss from operations | -$208.3M | -$202.5M |
| Interest income | $4.1M | $3.5M |
| Accretion (amortization) of investments | $2.5M | $3.5M |
| Change in fair value of short-term investment related party | $432.0K | -$485.0K |
| Other income, net | $148.0K | $41.0K |
| Total other income, net | $7.2M | $6.6M |
| Net loss attributable to common stockholders, basic | -$201.1M | -$195.9M |
| Net loss attributable to common stockholders, diluted | -$201.1M | -$195.9M |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$1.35 | -$1.65 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$1.35 | -$1.65 |
| Weighted-average common shares outstanding, diluted (in shares) | 148.8M shares | 118.6M shares |
| Weighted-average common shares outstanding, basic (in shares) | 148.8M shares | 118.6M shares |
| Net loss | -$201.1M | -$195.9M |
| Change in unrealized loss on investments, net of tax | $81.0K | $16.0K |
| Comprehensive loss | -$201.1M | -$195.9M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $63.0M | $182.5M | |
| Prepaid expenses | $2.9M | $6.8M | |
| Other current assets | $674.0K | $14.7M | |
| Total current assets | $181.3M | $211.9M | |
| Property and equipment, net | $20.6M | $24.4M | |
| Operating lease right-of-use assets | $126.2M | $47.2M | |
| Restricted cash | $13.7M | $14.1M | |
| Other assets | $1.0M | $0 | |
| Total assets | $342.7M | $297.5M | |
| Accounts payable | $8.9M | $11.4M | |
| Accrued expenses and other current liabilities | $12.6M | $15.9M | |
| Deferred revenue related party | $7.8M | $7.1M | |
| Operating lease liability | $8.1M | $3.6M | |
| Total current liabilities | $37.4M | $38.0M | |
| Deferred revenue, net of current related party | $58.1M | $63.2M | |
| Operating lease liability, net of current | $108.3M | $37.2M | |
| Research and development funding liability | $18.0M | $6.0M | |
| Total liabilities | $221.9M | $144.4M | |
| Common stock, par value of $0.00001 per share; 775,000,000 shares authorized; 180,514,014 and 131,160,842 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $2.0K | $2.0K | |
| Additional paid-in capital | $1.0B | $840.4M | |
| Accumulated other comprehensive income | $82.0K | $1.0K | |
| Accumulated deficit | -$888.4M | -$687.2M | |
| Total stockholders equity | $120.9M | $153.1M | $133.1M |
| Total liabilities and stockholders equity | $342.7M | $297.5M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 775.0M shares | 775.0M shares | |
| Common stock, shares issued (in shares) | 180.5M shares | 131.2M shares | |
| Common stock, shares outstanding (in shares) | 180.5M shares | 131.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $63.0M | $182.5M | |
| Prepaid expenses | $2.9M | $6.8M | |
| Other current assets | $674.0K | $14.7M | |
| Total current assets | $181.3M | $211.9M | |
| Property and equipment, net | $20.6M | $24.4M | |
| Operating lease right-of-use assets | $126.2M | $47.2M | |
| Restricted cash | $13.7M | $14.1M | |
| Other assets | $1.0M | $0 | |
| Total assets | $342.7M | $297.5M | |
| Accounts payable | $8.9M | $11.4M | |
| Accrued expenses and other current liabilities | $12.6M | $15.9M | |
| Deferred revenue related party | $7.8M | $7.1M | |
| Operating lease liability | $8.1M | $3.6M | |
| Total current liabilities | $37.4M | $38.0M | |
| Deferred revenue, net of current related party | $58.1M | $63.2M | |
| Operating lease liability, net of current | $108.3M | $37.2M | |
| Research and development funding liability | $18.0M | $6.0M | |
| Total liabilities | $221.9M | $144.4M | |
| Common stock, par value of $0.00001 per share; 775,000,000 shares authorized; 180,514,014 and 131,160,842 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $2.0K | $2.0K | |
| Additional paid-in capital | $1.0B | $840.4M | |
| Accumulated other comprehensive income | $82.0K | $1.0K | |
| Accumulated deficit | -$888.4M | -$687.2M | |
| Total stockholders equity | $120.9M | $153.1M | $133.1M |
| Total liabilities and stockholders equity | $342.7M | $297.5M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 775.0M shares | 775.0M shares | |
| Common stock, shares issued (in shares) | 180.5M shares | 131.2M shares | |
| Common stock, shares outstanding (in shares) | 180.5M shares | 131.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$201.1M | -$195.9M |
| Stock-based compensation expense | $29.3M | $26.1M |
| Non cash lease expense | $9.7M | $12.4M |
| Depreciation expense | $7.3M | $6.1M |
| Change in fair value of short-term investment related party | -$432.0K | $484.0K |
| Amortization of premiums and discount on short-term investments | -$1.9M | -$3.1M |
| Prepaid expenses and other current assets | $4.5M | -$15.9M |
| Accounts payable | $996.0K | -$5.3M |
| Accrued expenses and other current liabilities | -$1.2M | $1.8M |
| Accrued settlement payment related party | $0 | -$13.5M |
| Deferred revenue related party | -$4.4M | $70.3M |
| Lease liability | -$5.4M | -$6.5M |
| Net cash used in operating activities | -$162.6M | -$122.9M |
| Maturities of investments | $95.8M | $204.2M |
| Sales of investments related party | $5.4M | $0 |
| Purchases of investments | -$205.4M | -$129.4M |
| Purchases of property and equipment | -$4.5M | -$7.3M |
| Return (payment) of security deposit | $0 | $1.0M |
| Net cash (used in) provided by investing activities | -$108.8M | $68.5M |
| Proceeds from follow-on offering, net of issuance costs | $138.4M | $132.1M |
| Proceeds from research and development funding liability | $12.0M | $6.0M |
| Net proceeds from stock option exercises | $781.0K | $103.0K |
| Proceeds from ESPP offerings | $341.0K | $837.0K |
| Proceeds from issuance of common stock under the BMS Securities Purchase Agreement related party | $0 | $38.1M |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | $0 | $18.8M |
| Net cash provided by financing activities | $151.5M | $195.9M |
| Net change in cash, cash equivalents, and restricted cash | -$119.8M | $141.5M |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $83.8M | $44.9M |
| Decrease in right-of-use assets due to lease termination | $3.1M | $0 |
| Increase in right-of-use assets upon settlement with landlord | $10.9M | $0 |
| Purchases of property and equipment included in accounts payable and accrued expenses | $114.0K | $1.2M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Prime Medicine, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2025
- Chief executive officerAllan Reine May 19, 2025 to now10
- Chief financial officerSvetlana Ni Makhni Apr 17, 2026 to now11
- Chief financial officerAllan Reine Jan 19, 2024 to Apr 17, 202612
Board members and other officers (14)
- OfficerCarman Alenson Oct 19, 2022 to now13
- Chief Scientific OfficerJeremy Duffield Oct 19, 2022 to now14
- OfficerKeith Michael Gottesdiener Oct 19, 2022 to now15
- SVP, Strategy & Corporate Ops.Meredith Goldwasser Oct 19, 2022 to now16
- Chief Business OfficerRichard Brudnick Oct 19, 2022 to now17
- Board memberAllan Reine May 19, 2025 to now10
- Board memberJeffrey D. Marrazzo May 12, 2023 to now18
- Board memberDavid P. Schenkein Oct 19, 2022 to now19
- Board memberKaye I. Foster-Cheek Oct 19, 2022 to now20
- Board memberKeith Michael Gottesdiener Oct 19, 2022 to now15
- Board memberMichael Aaron Kelly Oct 19, 2022 to now21
- Board memberRobert Nelsen Oct 19, 2022 to now22
- Board memberThomas Cahill Oct 19, 2022 to now23
- Board memberWendy Chung Oct 19, 2022 to now24
Timeline
- May 19, 2025New chief executive Allan Reine becomes CEO10
Filings
279 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 43 major events, 121 insider forms, 18 large holders, 81 other. The latest 20:
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 8, 20268-K EDGAR
- Jun 8, 20264 EDGAR
- Jun 8, 20264 EDGAR
- Jun 8, 20264 EDGAR
- Jun 8, 20264 EDGAR
- Jun 8, 20264 EDGAR
- Jun 8, 20264 EDGAR
- Jun 8, 20264 EDGAR
- Jun 8, 20268-K EDGAR
- May 7, 202610-Q EDGAR
- May 7, 20268-K EDGAR
- Apr 23, 2026ARS EDGAR
- Apr 23, 2026DEFA14A EDGAR
- Apr 23, 2026DEF 14A EDGAR
- Apr 17, 20264 EDGAR
- Apr 17, 20263 EDGAR
- Apr 16, 20268-K EDGAR
- Mar 4, 2026EFFECT EDGAR
The 279 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
48 open-market trades by officers, directors and large owners since October 2021: 18 buys and 30 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | Alphabet Inc. | Buy | 1,500,000 | $3.30 | $5.0M | Form 4 |
| Aug 1, 2025 | NELSEN ROBERTDirector | Buy | 3,030,300 | $3.30 | $10.0M | Form 4 |
| Aug 1, 2025 | ARCH Venture Fund XII, L.P.10% owner | Buy | 3,030,300 | $3.30 | $10.0M | Form 4 |
| Aug 1, 2025 | GILLIS STEVEN10% owner | Buy | 3,030,300 | $3.30 | $10.0M | Form 4 |
| Jun 30, 2025 | Liu David R.10% owner | Buy | 21,000 | $2.52 | $52.9K | Form 4 |
| Jun 23, 2025 | Liu David R.10% owner | Buy | 21,000 | $2.16 | $45.4K | Form 4 |
| Jun 16, 2025 | Liu David R.10% owner | Buy | 21,000 | $1.49 | $31.3K | Form 4 |
| Jun 11, 2025 | Liu David R.10% owner | Buy | 21,000 | $1.60 | $33.6K | Form 4 |
| May 21, 2025 | LEE ANN L.Chief Technical Officer | Buy | 100,000 | $1.13 | $113.0K | Form 4 |
| May 21, 2025 | Reine AllanChief Executive Officer | Buy | 125,000 | $1.18 | $147.5K | Form 4 |
| May 20, 2025 | Brudnick RichardChief Business Officer | Buy | 20,000 | $1.19 | $23.8K | Form 4 |
| Feb 15, 2024 | NELSEN ROBERTDirector | Buy | 3,200,000 | $6.25 | $20.0M | Form 4 |
| Feb 15, 2024 | ARCH Venture Partners XII, LLC10% owner | Buy | 3,200,000 | $6.25 | $20.0M | Form 4 |
| Feb 15, 2024 | ARCH Venture Partners X, L.P.10% owner | Buy | 3,200,000 | $6.25 | $20.0M | Form 4 |
| Jun 21, 2023 | GV 2021 GP, L.P. | Sale | 19,003 | $14.97 | $284.5K | Form 4 |
| Jun 20, 2023 | GV 2021 GP, L.P. | Sale | 37,405 | $15.06 | $563.3K | Form 4 |
| Jun 16, 2023 | Alphabet Inc. | Sale | 6,532 | $15.02 | $98.1K | Form 4 |
| Jun 15, 2023 | Alphabet Inc. | Sale | 66,659 | $14.92 | $994.6K | Form 4 |
| Jun 14, 2023 | GV 2021 GP, L.P. | Sale | 28,960 | $14.87 | $430.6K | Form 4 |
| Jun 13, 2023 | GV 2021 GP, L.P. | Sale | 28,100 | $15.13 | $425.2K | Form 4 |
All 48 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A, 2 filings Nov 14, 2025 to Feb 17, 202625
- GV 2019, L.P.SCHEDULE 13G/A, 4 filings Feb 10, 2023 to Nov 12, 202526
- FMR LLCSCHEDULE 13G/A, 5 filings Oct 26, 2022 to Nov 5, 202527
- ARCH Venture Fund XII, L.P.SCHEDULE 13D/A, 3 filings Feb 22, 2024 to Aug 11, 202528
- Newpath Partners, L.P.SCHEDULE 13G/A, 2 filings Feb 7, 2023 to Feb 14, 202529
- ARCH Venture Fund X, L.P.SC 13G, 1 filing Feb 13, 202330
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Alphabet Inc. | 16,562,498 | $61.1M | 0.1% | No change |
| BlackRock, Inc. | 9,602,041 | $35.4M | 0.0% | +1,100,333 |
| ARK Investment Management LLC | 8,348,746 | $30.8M | 0.2% | +2,101,919 |
| State Street Corp | 7,576,460 | $28.0M | 0.0% | +1,231,335 |
| Vanguard Capital Management LLC | 4,522,640 | $16.7M | 0.0% | +48,478 |
| Balyasny Asset Management L.P. | 3,969,082 | $14.6M | 0.0% | −154,283 |
| Goldman Sachs Group Inc | 3,430,518 | $12.7M | 0.0% | +2,460,093 |
| Casdin Capital, LLC | 3,167,175 | $11.7M | 0.6% | No change |
| Woodline Partners LP | 3,003,904 | $11.1M | 0.0% | +591 |
| UBS Group AG | 2,794,689 | $10.3M | 0.0% | −93,729 |
| Geode Capital Management, LLC | 2,712,446 | $10.0M | 0.0% | −31,254 |
| Sumitomo Mitsui Trust Group, Inc. | 2,412,984 | $8.9M | 0.0% | −527,809 |
| Amova Asset Management Americas, Inc. | 2,407,018 | $8.9M | 0.1% | −533,775 |
| Citadel Advisors LLC | 2,054,543 | $7.6M | 0.0% | +1,718,185 |
| ADAR1 Capital Management, LLC | 1,997,552 | $7.4M | 0.3% | +24,270 |
| Fmr LLC | 1,761,884 | $6.5M | 0.0% | −7,592 |
| Two Sigma Investments, LP | 1,524,511 | $5.6M | 0.0% | −48,300 |
| Redmile Group, LLC | 1,389,632 | $5.1M | 0.3% | −201,200 |
| Farallon Capital Management, L.l.c. | 1,240,843 | $4.6M | 0.0% | No change |
| Jump Financial, LLC | 1,240,429 | $4.6M | 0.0% | New |
| Bank Of America Corp /de/ | 981,335 | $3.6M | 0.0% | +404,331 |
| Vanguard Portfolio Management LLC | 961,826 | $3.5M | 0.0% | +99,622 |
| Charles Schwab Investment Management Inc | 927,538 | $3.4M | 0.0% | +10,326 |
| Northern Trust Corp | 912,597 | $3.4M | 0.0% | +25,881 |
| Jpmorgan Chase & Co | 810,095 | $3.0M | 0.0% | −34,059 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARAllan Reine, Chief executive officer
- 11
- 12SEC EDGARAllan Reine, Chief financial officer
- 13SEC EDGARCarman Alenson, Officer
- 14
- 15SEC EDGARKeith Michael Gottesdiener, Officer
- 16
- 17
- 18SEC EDGARJeffrey D. Marrazzo, Board member
- 19SEC EDGARDavid P. Schenkein, Board member
- 20SEC EDGARKaye I. Foster-Cheek, Board member
- 21SEC EDGARMichael Aaron Kelly, Board member
- 22SEC EDGARRobert Nelsen, Board member
- 23SEC EDGARThomas Cahill, Board member
- 24SEC EDGARWendy Chung, Board member
- 25
- 26
- 27
- 28
- 29
- 30